Listas de seguimiento Ideas ProPicks IA Filtro Explorador de datos Gráficos Trabajo guardado

Brii Biosciences Limited

OTCPK:BRIBF

China / Salud / Biotecnología

Visión general

Finanzas históricas a 5 años

Precio

0.30 USD


Key Metrics	Latest
Total Revenue	38.38 M
Adjusted EBITDA	-488.5 M
EBITDA Margin	-1,272.8%
Net Profit Margin	-660.0%
Total Assets	2.897 B
Total Debt	1.899 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	12 Months	Jun-23	Jun-24

Revenue	20.20	82.22	92.54	122.28	56.32	38.38	40.10	22.16
% Growth		3.07	0.13	0.32	(0.54)			(0.45)

Adjusted EBITDA	(124.11)	(890.79)	(602.80)	(505.50)	(537.31)	(488.48)	(262.11)	(213.28)
% Margin	(6.15)	(10.83)	(6.51)	(4.13)	(9.54)	(12.73)	(6.54)	(9.63)

Adjusted EBIT	(126.92)	(896.97)	(610.48)	(513.85)	(544.30)	(493.62)	(266.28)	(215.60)
% Margin	(6.28)	(10.91)	(6.60)	(4.20)	(9.66)	(12.86)	(6.64)	(9.73)

Adjusted Net Income	(524.95)	(1,002.09)	(1,537.30)	(513.23)	(281.17)	(253.29)	(226.51)	(198.63)
% Margin	(25.99)	(12.19)	(16.61)	(4.20)	(4.99)	(6.60)	(5.65)	(8.97)

Adjusted Basic EPS	(2.94)	(5.24)	(3.50)	(0.71)	(0.39)	(0.35)	(0.31)	(0.27)

Cálculos de apoyo

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
CNY	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Jun-24	Jun-23	Jun-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	20	82	93	122	56	38	40	22
% Growth	NA	307.1%	12.6%	32.1%	-53.9%			-44.7%

Cost of Revenue	0	0	0	0	0	0	0	0
Gross Profit	20	82	93	122	56	38	40	22
% Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Research and Development	(84)	(876)	(495)	(441)	(403)	(327)	(202)	(126)
Selling and Marketing	0	0	0	(27)	(1)	(0)	(1)	0
General and Admin	(63)	(103)	(208)	(169)	(196)	(205)	(103)	(112)
Other Inc / (Exp)	(393)	(387)	(3,586)	(12)	252	114	23	(115)
Total Operating Exp	(540)	(1,366)	(4,289)	(648)	(348)	(418)	(283)	(353)

Operating Income	(520)	(1,284)	(4,196)	(526)	(292)	(380)	(243)	(331)
% Revenue	-2575.1%	-1562.0%	-4534.6%	-430.3%	-518.3%	-989.9%	-605.9%	-1493.9%

Interest Expense	(1)	1	5	36	108	109	46	48
Pre-tax Income	(521)	(1,284)	(4,191)	(490)	(184)	(271)	(197)	(283)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0
Net Income to Company	(521)	(1,284)	(4,191)	(490)	(184)	(271)	(197)	(283)
% Margin	-2579.9%	-1561.1%	-4528.8%	-400.5%	-327.3%	-705.5%	-490.9%	-1278.4%

Minority Interest in Earnings	0	94	27	5	10	5	7	3
Net Income to Stockholders	(521)	(1,190)	(4,164)	(484)	(175)	(265)	(190)	(281)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	(521)	(1,190)	(4,164)	(484)	(175)	(265)	(190)	(281)
% Margin	-2579.9%	-1446.9%	-4499.4%	-396.1%	-310.4%	-691.6%	-473.6%	-1266.2%

As Reported
Basic EPS (Continuing Ops)	(2.92)	(6.22)	(9.48)	(0.67)	(0.24)	(0.36)	(0.26)	(0.38)
Diluted EPS (Continuing Ops)	(2.92)	(6.22)	(9.48)	(0.67)	(0.24)	(0.36)	(0.26)	(0.38)

WA Basic Shares Out.	178.60	191.25	439.05	723.48	728.10	730.33	727.49	729.71
WA Diluted Shares Out.	178.60	191.25	439.05	723.48	728.10	730.33	727.49	729.71

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(521)	(1,284)	(4,191)	(490)	(184)	(271)	(197)	(283)
Addback: Net Interest Expense	1	(1)	(5)	(36)	(108)	(109)	(46)	(48)
Addback: Other Non Operating Expenses, Total	398	7	(0)	44	(122)	(137)	17	1
Addback: Depreciation & Amortization	3	6	8	8	7	5	4	2
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	(5)	15	(45)	(32)	(136)	24	(46)	114
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	5	0	5	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	365	3,631	0	0	0	0	0
Adjusted EBITDA	(124)	(891)	(603)	(505)	(537)	(488)	(262)	(213)
% Margin	-614.5%	-1083.4%	-651.4%	-413.4%	-954.0%	-1272.8%	-653.7%	-962.7%

Adjusted EBIT	(127)	(897)	(610)	(514)	(544)	(494)	(266)	(216)
% Margin	-628.5%	-1091.0%	-659.7%	-420.2%	-966.4%	-1286.1%	-664.1%	-973.1%

Adjusted Net Income Reconciliation
Net Income to Company	(521)	(1,284)	(4,191)	(490)	(184)	(271)	(197)	(283)
Addback: Unusual Items	(5)	380	3,586	(32)	(131)	24	(40)	114
Less: Tax Benefit of Unusual Items (26%)	1	(99)	(932)	8	34	(6)	10	(30)
Adjusted Net Income	(525)	(1,002)	(1,537)	(513)	(281)	(253)	(227)	(199)
% Margin	-2599.3%	-1218.8%	-1661.2%	-419.7%	-499.2%	-660.0%	-564.9%	-896.6%

Error de carga

Brii Biosciences Limited

OTCPK:BRIBF

China / Salud / Biotecnología

Finanzas históricas a 5 años